Neoadjuvant HER2+

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Latest News

Trastuzumab Deruxtecan Produces Activity in Metastatic Breast Cancer With Brain Mets, Irrespective of HER2 Status
Trastuzumab Deruxtecan Produces Activity in Metastatic Breast Cancer With Brain Mets, Irrespective of HER2 Status

November 1st 2022

Fam-trastuzumab deruxtecan-nxki induced meaningful antitumor activity in patients with HER2-positive, HER2-low, or HER2-negative metastatic breast cancer who presented with brain metastases at baseline.

Treatment Opportunities Expand for HER2+ Breast Cancer With Brain Metastases
Treatment Opportunities Expand for HER2+ Breast Cancer With Brain Metastases

October 31st 2022

Trastuzumab Deruxtecan Could Challenge Frontline Trastuzumab/Pertuzumab Combo in HER2+ Breast Cancer
Trastuzumab Deruxtecan Could Challenge Frontline Trastuzumab/Pertuzumab Combo in HER2+ Breast Cancer

October 27th 2022

Experts Navigate the New World of HER2-Positive Metastatic Breast Cancer
Experts Navigate the New World of HER2-Positive Metastatic Breast Cancer

October 19th 2022

Neoadjuvant Pegylated Liposomal Doxorubicin Regimen Has Promising Efficacy in HER2+ Breast Cancer
Neoadjuvant Pegylated Liposomal Doxorubicin Regimen Has Promising Efficacy in HER2+ Breast Cancer

October 7th 2022

Video Series
Video Interviews
Podcasts

More News